相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Function-Blocking ERBB3 Antibody Inhibits the Adaptive Response to RAF Inhibitor
Curtis H. Kugel et al.
CANCER RESEARCH (2014)
被撤回的出版物: An ATP-Competitive Inhibitor Modulates the Allosteric Function of the HER3 Pseudokinase (Retracted article. See vol. 24, pg. 917, 2017)
Peter Littlefield et al.
CHEMISTRY & BIOLOGY (2014)
ERBB3/HER2 Signaling Promotes Resistance to EGFR Blockade in Head and Neck and Colorectal Cancer Models
Li Zhang et al.
MOLECULAR CANCER THERAPEUTICS (2014)
Antagonism of EGFR and HER3 Enhances the Response to Inhibitors of the PI3K-Akt Pathway in Triple-Negative Breast Cancer
Jessica J. Tao et al.
SCIENCE SIGNALING (2014)
Intrinsic Resistance to MEK Inhibition in KRAS Mutant Lung and Colon Cancer through Transcriptional Induction of ERBB3
Chong Sun et al.
CELL REPORTS (2014)
An allosteric Sec61 inhibitor traps nascent transmembrane helices at the lateral gate
Andrew L. MacKinnon et al.
ELIFE (2014)
An Antibody That Locks HER3 in the Inactive Conformation Inhibits Tumor Growth Driven by HER2 or Neuregulin
Andrew P. Garner et al.
CANCER RESEARCH (2013)
Melanoma adapts to RAF/MEK inhibitors through FOXD3-mediated upregulation of ERBB3
Ethan V. Abel et al.
JOURNAL OF CLINICAL INVESTIGATION (2013)
Activation of an early feedback survival loop involving phospho-ErbB3 is a general response of melanoma cells to RAF/MEK inhibition and is abrogated by anti-ErbB3 antibodies
Luigi Fattore et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2013)
Proliferation of Colorectal Cancer Is Promoted by Two Signaling Transduction Expression Patterns: ErbB2/ErbB3/AKT and MET/ErbB3/MAPK
Yong-Liang Yao et al.
PLOS ONE (2013)
Activating HER2 Mutations in HER2 Gene Amplification Negative Breast Cancer
Ron Bose et al.
CANCER DISCOVERY (2013)
A High-Throughput Cell-Based Gaussia Luciferase Reporter Assay for Identifying Modulators of Fibulin-3 Secretion
John D. Hulleman et al.
JOURNAL OF BIOMOLECULAR SCREENING (2013)
HER3 signalling is regulated through a multitude of redundant mechanisms in HER2-driven tumour cells
Dhara N. Amin et al.
BIOCHEMICAL JOURNAL (2012)
A monoclonal antibody to the human HER3 receptor inhibits Neuregulin 1-beta binding and co-operates with Herceptin in inhibiting the growth of breast cancer derived cell lines
Edith Blackburn et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
HER3 Is Required for HER2-Induced Preneoplastic Changes to the Breast Epithelium and Tumor Formation
David B. Vaught et al.
CANCER RESEARCH (2012)
Increasing Potential of HER3 Signaling in Colon Cancer Progression and Therapy
Christian Gespach
CLINICAL CANCER RESEARCH (2012)
Toward the Prognostic Significance and Therapeutic Potential of HER3 Receptor Tyrosine Kinase in Human Colon Cancer
Abdelhamid Beji et al.
CLINICAL CANCER RESEARCH (2012)
ErbB3 Inhibitory Surrobodies Inhibit Tumor Cell Proliferation In Vitro and In Vivo
Pamela K. Foreman et al.
MOLECULAR CANCER THERAPEUTICS (2012)
Antitumor Activity of a Novel Bispecific Antibody That Targets the ErbB2/ErbB3 Oncogenic Unit and Inhibits Heregulin-Induced Activation of ErbB3
Charlotte F. McDonagh et al.
MOLECULAR CANCER THERAPEUTICS (2012)
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
Jose Baselga et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study
L. Licitra et al.
ANNALS OF ONCOLOGY (2011)
Secretory Protein Profiling Reveals TNF-α Inactivation by Selective and Promiscuous Sec61 Modulators
Sarah V. Maifeld et al.
CHEMISTRY & BIOLOGY (2011)
Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase
Joan T. Garrett et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
An Activated ErbB3/NRG1 Autocrine Loop Supports In Vivo Proliferation in Ovarian Cancer Cells
Qing Sheng et al.
CANCER CELL (2010)
An ErbB3 Antibody, MM-121, Is Active in Cancers with Ligand-Dependent Activation
Birgit Schoeberl et al.
CANCER RESEARCH (2010)
Geldanamycin selectively targets the nascent form of ERBB3 for degradation
Candice S. Gerbin et al.
CELL STRESS & CHAPERONES (2010)
Resiliency and Vulnerability in the HER2-HER3 Tumorigenic Driver
Dhara N. Amin et al.
SCIENCE TRANSLATIONAL MEDICINE (2010)
Structural analysis of the catalytically inactive kinase domain of the human EGF receptor 3
Natalia Jura et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
A central role for HER3 in HER2-amplified breast cancer:: implications for targeted therapy
Si Tuen Lee-Hoeflich et al.
CANCER RESEARCH (2008)
HER3 is a determinant for poor prognosis in melanoma
Markus Reschke et al.
CLINICAL CANCER RESEARCH (2008)
Photo-leucine incorporation reveals the target of a cyclodepsipeptide inhibitor of cotranslational translocation
Andrew L. MacKinnon et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2007)
Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3
Natalia V. Sergina et al.
NATURE (2007)
Epidermal growth factor receptor mutations in lung cancer
Sreenath V. Sharma et al.
NATURE REVIEWS CANCER (2007)
Lapatinib plus capecitabine for HER2-positive advanced breast cancer
Charles E. Geyer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
The translocation inhibitor CAM741 interferes with vascular cell adhesion molecule 1 signal peptide insertion at the translocon
Hanna Harant et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Amplification of c-erbB2 oncogene - A maior prognostic indicator in uterine serous papillaty carcinoma
AD Santin et al.
CANCER (2005)
Selective inhibition of cotranslational translocation of vascular cell adhesion molecule 1
J Besemer et al.
NATURE (2005)
A substrate-specific inhibitor of protein translocation into the endoplasmic reticulum
JL Garrison et al.
NATURE (2005)
Somatic mutations of the HER2 kinase domain in lung adenocarcinomas
H Shigematsu et al.
CANCER RESEARCH (2005)
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
TJ Lynch et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation
T Holbro et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Solution-phase parallel synthesis of a pharmacophore library of HUN-7293 analogues: A general chemical mutagenesis approach to defining structure-function properties of naturally occurring cyclic (depsi)peptides
Y Chen et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2002)
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
DJ Slamon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
分享论文
